Studio prospettico in aperto sull'efficacia e la tollerabilità a lungo termine del Levetiracetam corne terapia aggiuntiva in pazienti con epilessia parziale farmacoresistente

Translated title of the contribution: Efficacy and safety of Levetiracetam as add-on therapy in patients with refractory partial epilepsy: A long-term, open-label, prospective study

A. La Neve, G. Boero, M. Stuppiello, A. Papantonio, N. Specchio, P. D'Alessandro, A. De Palo, G. De Agazio, M. Plantamura, M. Santosabato, T. Francavilla, S. Ottaviano, L. M. Specchio

Research output: Contribution to journalArticle

Abstract

We investigated the long-term efficacy and tolerability of Levetiracetam as add-on therapy in refractory partial epilepsy. 160 patients (76 M) were enrolled; during three months before Levetiracetam was started seizure monthly frequency was 9.3+13.4 (range 0.7-94); during last three months in the observational period the seiizure frequency was 5.8+12.16 (range 0-86.6) (p <0.001). 40 (28%) patients were seizure free, 42 (30%) responders, 42 (30%) immodified and 18 (12%) patients were worsened. After 1 year 99 (71%) patients were till in the study. 22 (14%) patients withdrew the Levetiracetam because of adverse effects most commonly nervousness. This study confirm that the effectiveness of Levetiracetam in refractory partial epilepsy is maintened in the long period.

Original languageItalian
Pages (from-to)195-197
Number of pages3
JournalBollettino - Lega Italiana contro l'Epilessia
Issue number125-126
Publication statusPublished - Jul 2004

Fingerprint

etiracetam
Partial Epilepsy
Prospective Studies
Safety
Seizures
Therapeutics
Anxiety

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Studio prospettico in aperto sull'efficacia e la tollerabilità a lungo termine del Levetiracetam corne terapia aggiuntiva in pazienti con epilessia parziale farmacoresistente. / La Neve, A.; Boero, G.; Stuppiello, M.; Papantonio, A.; Specchio, N.; D'Alessandro, P.; De Palo, A.; De Agazio, G.; Plantamura, M.; Santosabato, M.; Francavilla, T.; Ottaviano, S.; Specchio, L. M.

In: Bollettino - Lega Italiana contro l'Epilessia, No. 125-126, 07.2004, p. 195-197.

Research output: Contribution to journalArticle

La Neve, A, Boero, G, Stuppiello, M, Papantonio, A, Specchio, N, D'Alessandro, P, De Palo, A, De Agazio, G, Plantamura, M, Santosabato, M, Francavilla, T, Ottaviano, S & Specchio, LM 2004, 'Studio prospettico in aperto sull'efficacia e la tollerabilità a lungo termine del Levetiracetam corne terapia aggiuntiva in pazienti con epilessia parziale farmacoresistente', Bollettino - Lega Italiana contro l'Epilessia, no. 125-126, pp. 195-197.
La Neve, A. ; Boero, G. ; Stuppiello, M. ; Papantonio, A. ; Specchio, N. ; D'Alessandro, P. ; De Palo, A. ; De Agazio, G. ; Plantamura, M. ; Santosabato, M. ; Francavilla, T. ; Ottaviano, S. ; Specchio, L. M. / Studio prospettico in aperto sull'efficacia e la tollerabilità a lungo termine del Levetiracetam corne terapia aggiuntiva in pazienti con epilessia parziale farmacoresistente. In: Bollettino - Lega Italiana contro l'Epilessia. 2004 ; No. 125-126. pp. 195-197.
@article{d54a61eaa6254bd49f84d3ca3560f129,
title = "Studio prospettico in aperto sull'efficacia e la tollerabilit{\`a} a lungo termine del Levetiracetam corne terapia aggiuntiva in pazienti con epilessia parziale farmacoresistente",
abstract = "We investigated the long-term efficacy and tolerability of Levetiracetam as add-on therapy in refractory partial epilepsy. 160 patients (76 M) were enrolled; during three months before Levetiracetam was started seizure monthly frequency was 9.3+13.4 (range 0.7-94); during last three months in the observational period the seiizure frequency was 5.8+12.16 (range 0-86.6) (p <0.001). 40 (28{\%}) patients were seizure free, 42 (30{\%}) responders, 42 (30{\%}) immodified and 18 (12{\%}) patients were worsened. After 1 year 99 (71{\%}) patients were till in the study. 22 (14{\%}) patients withdrew the Levetiracetam because of adverse effects most commonly nervousness. This study confirm that the effectiveness of Levetiracetam in refractory partial epilepsy is maintened in the long period.",
keywords = "Levetiracetam, Long-term Efficacy, Refractory Partial Epilepsy",
author = "{La Neve}, A. and G. Boero and M. Stuppiello and A. Papantonio and N. Specchio and P. D'Alessandro and {De Palo}, A. and {De Agazio}, G. and M. Plantamura and M. Santosabato and T. Francavilla and S. Ottaviano and Specchio, {L. M.}",
year = "2004",
month = "7",
language = "Italian",
pages = "195--197",
journal = "Bollettino - Lega Italiana contro l'Epilessia",
issn = "0394-560X",
publisher = "Lega Italiana contro l'Epilessia",
number = "125-126",

}

TY - JOUR

T1 - Studio prospettico in aperto sull'efficacia e la tollerabilità a lungo termine del Levetiracetam corne terapia aggiuntiva in pazienti con epilessia parziale farmacoresistente

AU - La Neve, A.

AU - Boero, G.

AU - Stuppiello, M.

AU - Papantonio, A.

AU - Specchio, N.

AU - D'Alessandro, P.

AU - De Palo, A.

AU - De Agazio, G.

AU - Plantamura, M.

AU - Santosabato, M.

AU - Francavilla, T.

AU - Ottaviano, S.

AU - Specchio, L. M.

PY - 2004/7

Y1 - 2004/7

N2 - We investigated the long-term efficacy and tolerability of Levetiracetam as add-on therapy in refractory partial epilepsy. 160 patients (76 M) were enrolled; during three months before Levetiracetam was started seizure monthly frequency was 9.3+13.4 (range 0.7-94); during last three months in the observational period the seiizure frequency was 5.8+12.16 (range 0-86.6) (p <0.001). 40 (28%) patients were seizure free, 42 (30%) responders, 42 (30%) immodified and 18 (12%) patients were worsened. After 1 year 99 (71%) patients were till in the study. 22 (14%) patients withdrew the Levetiracetam because of adverse effects most commonly nervousness. This study confirm that the effectiveness of Levetiracetam in refractory partial epilepsy is maintened in the long period.

AB - We investigated the long-term efficacy and tolerability of Levetiracetam as add-on therapy in refractory partial epilepsy. 160 patients (76 M) were enrolled; during three months before Levetiracetam was started seizure monthly frequency was 9.3+13.4 (range 0.7-94); during last three months in the observational period the seiizure frequency was 5.8+12.16 (range 0-86.6) (p <0.001). 40 (28%) patients were seizure free, 42 (30%) responders, 42 (30%) immodified and 18 (12%) patients were worsened. After 1 year 99 (71%) patients were till in the study. 22 (14%) patients withdrew the Levetiracetam because of adverse effects most commonly nervousness. This study confirm that the effectiveness of Levetiracetam in refractory partial epilepsy is maintened in the long period.

KW - Levetiracetam

KW - Long-term Efficacy

KW - Refractory Partial Epilepsy

UR - http://www.scopus.com/inward/record.url?scp=22944437809&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=22944437809&partnerID=8YFLogxK

M3 - Articolo

AN - SCOPUS:22944437809

SP - 195

EP - 197

JO - Bollettino - Lega Italiana contro l'Epilessia

JF - Bollettino - Lega Italiana contro l'Epilessia

SN - 0394-560X

IS - 125-126

ER -